ETFs & MarketsBasicMirum and Incyte Zilurgisertib Approval: What It Means for Biotech ETFs
Regulators have officially cleared zilurgisertib for the treatment of a rare bone disorder, marking a significant commercial milestone for Mirum Pharmaceuticals and Incyte. This approval serves as a potential catalyst for volatility within specialized biotechnology indices and sector-specific funds.
Published 1 hour ago
Read more →